Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting
Launched by STUART WILLICK · Jan 19, 2017
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
Clomiphene, pharmaceutically prepared as clomiphene citrate, is a selective estrogen receptor modulator (SERM) with a therapeutic indication to treat female infertility. Though FDA-approved only for use in women, clomiphene is often prescribed off-label to males to treat male infertility and secondary hypogonadism due to its ability to increase serum testosterone levels. Numerous clinical studies have documented both the effectiveness for these indications and safety of clomiphene administration in males. Increasing the concentration of circulating testosterone can have additional effects, ...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • - Active males who engage in regular exercise between the ages of 18 and 40 on the day of enrollment
- • • For this study, regular exercise is defined as: physical activity resulting in an increased heart rate for at least 30 minutes per day, 4-5 days per week.
- Exclusion Criteria:
- • Individuals outside of the described age range on the day of enrollment
- • Individuals who are in a Registered Testing Pool for anti-doping purposes, or individuals who for any reason could be subject to doping control testing
- • Individuals who are unwilling or unable to provide blood or urine samples
- • Individuals who do not actively exercise
- • Individuals with any history of cancer, cardiovascular disease, endocrine abnormalities, infertility, hypoandrogenism, renal disease, hepatic disease, neurologic disease, or any psychiatric history
- • Individuals who have previously used anabolic steroids, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), or who are currently using any substances included on the WADA Prohibited List
- • History of venous thromboembolic disease (i.e. deep vein thrombosis or pulmonary embolism)
- • History of untreated cataracts
- • History of intracranial lesions such as pituitary tumors
- • Transaminase elevation greater than 3 times the upper limit of normal (ULN)
- • Moderate or heavy alcohol intake
About Stuart Willick
Stuart Willick is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, Mr. Willick leverages extensive expertise in clinical development and regulatory compliance to design and implement rigorous trial protocols. His collaborative approach fosters partnerships with healthcare professionals and research institutions, ensuring the highest standards of integrity and scientific excellence. Driven by a passion for healthcare innovation, Stuart Willick aims to contribute significantly to the understanding and treatment of various medical conditions through well-structured clinical studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Stuart Willick, MD
Principal Investigator
University of Utah
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials